238 related articles for article (PubMed ID: 9066354)
1. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
[TBL] [Abstract][Full Text] [Related]
2. Dopamine autoreceptor function is lost in advanced Parkinson's disease.
Ekesbo A; Rydin E; Torstenson R; Sydow O; Låengström B; Tedroff J
Neurology; 1999 Jan; 52(1):120-5. PubMed ID: 9921858
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
4. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Tedroff J; Aquilonius SM; Hartvig P; Bredberg E; Bjurling P; Långström B
Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
[TBL] [Abstract][Full Text] [Related]
5. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
6. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
7. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
9. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
10. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
13. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
Behav Brain Res; 2012 Apr; 230(1):116-24. PubMed ID: 22343069
[TBL] [Abstract][Full Text] [Related]
14. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
16. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
[TBL] [Abstract][Full Text] [Related]
17. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
Neurology; 2000 Apr; 54(7):1482-7. PubMed ID: 10751262
[TBL] [Abstract][Full Text] [Related]
18. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
19. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
[TBL] [Abstract][Full Text] [Related]
20. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Guttman M; Stewart D; Hussey D; Wilson A; Houle S; Kish S
Neurology; 2001 Jun; 56(11):1559-64. PubMed ID: 11402115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
